Circulating Levels of Proprotein Convertase Subtilisin/kexin Type 9 (pcsk9) are Associated With Monocyte Subsets in Patients With Stable Coronary Artery Disease

被引：0
|
作者：
Krychtiuk, Konstantin
Lenz, Max
Hohensinner, Philipp
Distelmaier, Klaus
Schrutka, Lore
Kastl, Stefan
Pfaffenberger, Stefan
Huber, Kurt
Hengstenberg, Christian
Wojta, Johann
Speidl, Walter S.
机构：
来源：
CIRCULATION | 2020年 / 142卷
关键词：
D O I：
10.1161/circ.142.suppl_3.15930
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A15930
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease
    Krychtiuk, Konstantin A.
    Lenz, Max
    Hohensinner, Philipp
    Distelmaier, Klaus
    Schrutka, Lore
    Kastl, Stefan P.
    Huber, Kurt
    Dostal, Elisabeth
    Oravec, Stanislav
    Hengstenberg, Christian
    Wojta, Johann
    Speidl, Walter S.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2021, 15 (03) : 512 - 521
  • [2] CIRCULATING LEVELS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK-9) ARE ASSOCIATED WITH MONOCYTE SUBSETS IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE
    Krychtiuk, Konstantin A.
    Lenz, Max
    Kastl, Stefan
    Pfaffenberger, Stefan
    Hofbauer, Sebastian
    Brekalo, Mira
    Huber, Kurt
    Hengstenberg, Christian
    Wojta, Johann
    Speidl, Walter S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 95 - 95
  • [3] Proprotein convertase subtilisin/kexin type 9 (PCSK9) plasma levels are associated with the metabolic syndrome in patients with stable coronary artery disease
    Caselli, C.
    Ragusa, R.
    Del Turco, S.
    Basta, G.
    Saraste, A.
    Knuuti, J.
    De Caterina, R.
    Neglia, D.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3802 - 3802
  • [4] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors
    Avci, Ahmet
    Demir, Kenan
    Altunkeser, Bulent Behlul
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2014, 42 : 56 - 67
  • [5] Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment
    Werner, Christian
    Hoffmann, Michael M.
    Winkler, Karl
    Boehm, Michael
    Laufs, Ulrich
    VASCULAR PHARMACOLOGY, 2014, 62 (02) : 94 - 102
  • [6] Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
    Tsuyoshi Nozue
    Hiroaki Hattori
    Kazuyuki Ogawa
    Takeshi Kujiraoka
    Tadao Iwasaki
    Tsutomu Hirano
    Ichiro Michishita
    Lipids in Health and Disease, 15
  • [7] Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
    Nozue, Tsuyoshi
    Hattori, Hiroaki
    Ogawa, Kazuyuki
    Kujiraoka, Takeshi
    Iwasaki, Tadao
    Hirano, Tsutomu
    Michishita, Ichiro
    LIPIDS IN HEALTH AND DISEASE, 2016, 15 : 1 - 7
  • [8] Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
    Leong, Derek
    Wu, Peter E.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (32) : E894 - E894
  • [9] PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9): A Narrative Review
    Dua, Pamila
    Reeta, K. H.
    JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES, 2020, 6 (03) : 226 - 233
  • [10] Regulation of ENaC by proprotein convertase subtilisin/kexin type 9(PCSK9)
    Sharotri, Vikas
    Snyder, Peter M.
    FASEB JOURNAL, 2010, 24
12345